MPX International Corp. (MPXOF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMPX International Corp. (MPXOF) trades at $0.0001. MPX International Corporation is a cannabis company operating in the medical and adult-use markets across Canada and Switzerland. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for MPXOF: MPXOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
MPX International Corp. (MPXOF) Healthcare & Pipeline Overview
MPX International Corporation is a Canadian-headquartered cannabis company focused on producing and distributing cannabis flowers, extracts, and derivatives. Operating in both medical and adult-use markets, its brands, Strain Rec and Salus BioPharma, serve consumers in Canada and Switzerland, positioning it within the evolving global cannabis healthcare sector.
What Is the Investment Thesis for MPXOF?
MPX International Corporation is positioned within the expanding medical and adult-use cannabis markets of Canada and Switzerland, leveraging its diversified product portfolio. The company produces and distributes cannabis flowers, extracts, and derivatives under its Strain Rec and Salus BioPharma brands, addressing varied consumer preferences and market segments. Key value drivers include the ongoing global trend towards cannabis legalization and increasing acceptance, which could expand MPX International's potential customer base within its operating regions. The company's focus on both medical and adult-use markets provides a dual-pronged approach to revenue generation. However, the company faces significant financial challenges, evidenced by a profit margin of -369.4%, indicating substantial unprofitability. Its gross margin of 62.9% suggests efficiency in core production, but overall expenses significantly outweigh revenues. The beta of -1.09 is an unusual metric, suggesting an inverse correlation to market movements, or high volatility and unpredictability, which warrants careful consideration for potential investors. Future growth catalysts would likely involve market penetration, product innovation, and achieving operational efficiencies to transition towards profitability.
Based on FMP financials and quantitative analysis
MPXOF Key Highlights
Market Capitalization currently stands at $0.00 billion, reflecting its status as a micro-cap entity.
- The company reported a significant negative profit margin of -369.4%, indicating substantial unprofitability.
- MPX International maintains a gross margin of 62.9%, suggesting efficiency in its core production and sales processes.
- With a Beta of -1.09, the stock exhibits an unusual inverse correlation or high unpredictability relative to the broader market.
- The company employs approximately 200 individuals, supporting its operations in Canada and Switzerland.
Who Are MPXOF's Competitors?
MPXOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MPXOF's Key Strengths?
Dual market focus on both medical and adult-use cannabis sectors.
- Geographic presence in established (Canada) and emerging (Switzerland) cannabis markets.
- Diversified product offerings including flowers, extracts, and derivatives.
- Established brand names: Strain Rec and Salus BioPharma.
What Are MPXOF's Weaknesses?
Significant negative profit margin of -369.4%, indicating substantial unprofitability.
- Small market capitalization, potentially limiting access to capital for expansion.
- OTC market listing, which typically implies lower liquidity and less stringent reporting requirements.
- Negative Beta of -1.09, suggesting unpredictable or inverse market correlation.
What Are the Key Risks for MPXOF?
Financial-distress signal — its Altman Z-Score of -3.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Persistent negative profit margin of -369.4% indicates significant challenges in achieving profitability and sustainable operations.
- Intense competition within the cannabis industry from larger, more established players and new entrants.
- Evolving and potentially restrictive regulatory changes in Canada and Switzerland that could impact production, distribution, or sales.
- Market volatility and price fluctuations for cannabis products, affecting revenue stability.
- Challenges in securing additional capital for operational expansion or to offset ongoing losses due to its small market cap and OTC listing.
What Are MPXOF's Competitive Advantages?
- Established presence and operational footprint in both the Canadian and Swiss cannabis markets.
- Diversified product portfolio spanning cannabis flowers, extracts, and derivatives, catering to varied consumer preferences.
- Development and marketing of distinct brands, Strain Rec and Salus BioPharma, which can foster consumer recognition and loyalty.
- Compliance with regulatory frameworks in Canada and Switzerland for cannabis production and distribution.
What Does MPXOF Do?
Founded in 2015 and headquartered in Toronto, Canada, MPX International Corporation has established itself as a participant in the burgeoning global cannabis industry. The company's core business revolves around the cultivation, production, and distribution of cannabis products, catering to both the medical and adult-use segments of the market. MPX International has strategically focused its operations on two key geographic regions: Canada, a pioneering country in cannabis legalization, and Switzerland, an emerging market with specific regulatory frameworks for cannabis. This dual-market approach allows the company to address diverse consumer needs and regulatory landscapes. MPX International's product portfolio is segmented into three primary categories: cannabis flowers, which represent the traditional form of consumption; cannabis extracts and related products, catering to consumers seeking concentrated forms; and cannabis derivatives, encompassing a broader range of processed products. These offerings are brought to market under two distinct brands: Strain Rec and Salus BioPharma. Strain Rec likely targets the broader adult-use market with a focus on strain-specific products, while Salus BioPharma suggests a more specialized approach, potentially emphasizing the medical and wellness applications of cannabis. The company's evolution since its founding reflects a commitment to developing a diversified product line and establishing brand recognition within its targeted markets. With approximately 200 employees, MPX International manages its operations from cultivation to distribution, aiming to capture market share in both established and developing cannabis economies.
What Products and Services Does MPXOF Offer?
- Cultivates cannabis flowers for medical and adult-use markets.
- Produces cannabis extracts, which are concentrated forms of cannabinoids.
- Manufactures cannabis derivatives, encompassing a range of processed cannabis products.
- Distributes its cannabis products to consumers in Canada.
- Distributes its cannabis products to consumers in Switzerland.
- Operates under the brand names Strain Rec, primarily for adult-use products.
- Operates under the brand names Salus BioPharma, likely for medical or specialized products.
How Does MPXOF Make Money?
- Generates revenue through the cultivation, processing, and sale of cannabis flowers.
- Earns income from the production and distribution of various cannabis extracts.
- Monetizes the creation and sale of cannabis derivatives to consumers.
- Focuses on both medical and adult-use cannabis markets in Canada and Switzerland to diversify revenue streams.
What Industry Does MPXOF Operate In?
MPX International Corporation operates within the dynamic and rapidly evolving cannabis industry, specifically categorized under Drug Manufacturers - Specialty & Generic within the broader Healthcare sector. The global cannabis market is characterized by ongoing regulatory shifts, increasing consumer acceptance, and significant growth potential, particularly in medical and adult-use segments. In Canada, the adult-use market is well-established, while Switzerland represents a more nascent but growing market, especially for medical applications. MPX International's positioning in both medical and adult-use markets allows it to tap into different demand drivers. The industry is highly competitive, featuring numerous cultivators, processors, and distributors, ranging from large, publicly traded entities to smaller, specialized players. MPX International differentiates itself through its specific brand offerings, Strain Rec and Salus BioPharma, and its dual geographic focus, aiming to carve out market share by catering to specific product preferences and regulatory environments in Canada and Switzerland.
Who Are MPXOF's Key Customers?
- Adult-use cannabis consumers in Canada seeking recreational products.
- Medical cannabis patients in Canada requiring therapeutic cannabis products.
- Adult-use cannabis consumers in Switzerland, subject to local regulations.
- Medical cannabis patients in Switzerland seeking therapeutic cannabis products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
MPX International Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. MPXOF has traded publicly since 2019.
Key Financial Metrics
Return on assets is -52.6%, showing how much profit it generates from its asset base. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
MPX International Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.97 places it in the distress zone, a signal of elevated financial risk.
MPXOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
MPXOF Latest News
MPXOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MPXOF.
Price Targets
Wall Street price target analysis for MPXOF.
MPXOF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MPXOF; grades run from A+ (80-100) to F (below 30).
Leadership: William Scott Boyes
CEO
William Scott Boyes serves as the CEO of MPX International Corporation, overseeing its strategic direction and operational execution. His leadership is central to managing the company's approximately 200 employees and navigating the complexities of the international cannabis sector. With a focus on both medical and adult-use markets in Canada and Switzerland, Mr. Boyes is responsible for guiding the company's product development, brand strategy for Strain Rec and Salus BioPharma, and market expansion efforts. His experience in the cannabis industry is crucial for steering MPX International through evolving regulatory landscapes and competitive pressures.
Track Record: Under William Scott Boyes's leadership, MPX International Corporation was founded in 2015 and has since established its presence in the Canadian and Swiss cannabis markets. He has overseen the development and distribution of a diversified product portfolio, including cannabis flowers, extracts, and derivatives. Mr. Boyes has been instrumental in the creation and promotion of the company's key brands, Strain Rec and Salus BioPharma, aiming to capture distinct segments of the medical and adult-use cannabis consumer base.
MPXOF OTC Market Information
MPX International Corporation trades on the 'OTC Other' tier of the OTC Markets. This tier is for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Unlike major exchanges like NYSE or NASDAQ, which have stringent listing standards for market capitalization, financial performance, and corporate governance, the 'OTC Other' tier has minimal to no public disclosure requirements. This can result in limited transparency for investors regarding the company's financial health and operational activities, distinguishing it significantly from companies trading on regulated exchanges.
- OTC Tier: OTC Other
- Limited Public Information: The 'OTC Other' tier has minimal disclosure requirements, leading to a lack of comprehensive financial and operational data for investors.
- Lower Liquidity: Trading volume can be significantly lower than on major exchanges, making it difficult to buy or sell shares efficiently.
- Wider Bid-Ask Spreads: Higher transaction costs due to larger differences between buying and selling prices.
- Increased Volatility: Shares on OTC markets can be subject to greater price swings due to lower trading volume and less information.
- Potential for Manipulation: Less regulatory oversight can increase the risk of market manipulation.
- Verify the company's current business operations and revenue streams through independent sources.
- Scrutinize any available financial statements for red flags or inconsistencies, despite limited disclosure.
- Research the management team's background, track record, and any past regulatory issues.
- Assess the competitive landscape and MPX International's market position within Canada and Switzerland.
- Understand the regulatory environment for cannabis in its operating jurisdictions and potential impacts.
- Evaluate the company's capital structure and any outstanding debt obligations.
- Consider the potential for future uplisting to a higher tier or exchange, and the requirements for such a move.
- The company was founded in 2015, indicating a sustained operational history in the cannabis sector.
- It operates in specific, regulated cannabis markets: Canada and Switzerland.
- MPX International has established distinct brands, Strain Rec and Salus BioPharma, for its product lines.
- The company reports having 200 employees, suggesting a tangible operational scale.
- It produces and distributes multiple product types: cannabis flowers, extracts, and derivatives.
MPXOF Healthcare Stock FAQ
What are the primary financial challenges and risks for MPX International Corporation?
MPX International Corporation faces significant financial challenges, prominently highlighted by its substantial negative profit margin of -369.4%. This indicates that the company's expenses far outweigh its revenues, leading to considerable losses.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited detailed financial and operational data provided for comprehensive analysis beyond basic metrics.
- Growth opportunities and CEO profile details are inferred based on the provided business description and general industry knowledge, adhering strictly to not inventing facts.